{"version":"1.0","provider_name":"Live Magazine","provider_url":"https:\/\/www.livemag.it","author_name":"italpress","author_url":"https:\/\/www.livemag.it\/index.php\/author\/italpress\/","title":"BPCO non controllata, via libera a Dupilumab - Live Magazine","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"srM92hSc9n\"><a href=\"https:\/\/www.livemag.it\/index.php\/2024\/08\/09\/bpco-non-controllata-via-libera-a-dupilumab\/\">BPCO non controllata, via libera a Dupilumab<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.livemag.it\/index.php\/2024\/08\/09\/bpco-non-controllata-via-libera-a-dupilumab\/embed\/#?secret=srM92hSc9n\" width=\"600\" height=\"338\" title=\"&#8220;BPCO non controllata, via libera a Dupilumab&#8221; &#8212; Live Magazine\" data-secret=\"srM92hSc9n\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.livemag.it\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/www.livemag.it\/wp-content\/uploads\/2024\/02\/ograph.jpg","thumbnail_width":1200,"thumbnail_height":675,"description":"ROMA (ITALPRESS) &#8211; L&#8217;Agenzia Europea dei Medicinali ha approvato dupilumab, anticorpo monoclonale completamente umano, come trattamento aggiuntivo di mantenimento per gli adulti affetti da broncopneumopatia cronica ostruttiva non controllata, caratterizzata da un aumento degli eosinofili nel sangue. L&#8217;approvazione dell\u2019EMA si basa sui risultati di due storici studi di fase 3 che sono stati pubblicati separatamente [&hellip;]"}